Consensus on cerebral involvement in myotonic dystrophy. Workshop report: May 24-27, 2013, Ferrere (AT), Italy

Neuromuscular Disorders

Volumn 24, Issue 5, 2014, Pages 445-452

  Bugiardini, Enrico ^b   Meola, G ^a   Alvarez, Carmen ^b   Angeard, Nathalie ^b   Bassez, Guillaume ^b   Day, John W ^b   Dent, Gersham ^b   Ekström, Anne Berit ^b   Eymard, Bruno ^b   Fossati, Barbara ^b   Gagnon, Cynthia ^b   Gomes Pereira, Mario ^b   Gourdon, Geneviè ^b   Heatwole, Chad ^b   Housman, David E ^b   Johnson, Nicholas E ^b   Kornblum, Cornelia ^b   MacKenzie, Don ^c   Minnerop, Martina ^b   Morris, Carl ^b   Nishino, Seiji ^b   Pearson, Christopher E ^b   Pletcher, Mat ^b   Ranum, Laura ^b   Reddy, Sita ^b   Richer, Louis ^b   Schoser, Benedikt ^b   Sergeant, Nicolas ^b   Wang, Eric ^b   Wentworth, Bruce ^b   Winblad, Stefan ^b   Wozniak, Jeffrey ^b   Swanson, Maurice S ^b   Ladd, Andrea ^b   more..

^a UNIVERSITY OF MILAN   (Italy)

^b Marigold Foundation ^*

^c Marigold Foundation   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BRAIN DYSFUNCTION; BRAIN TISSUE; CHILDHOOD DISEASE; CLINICAL RESEARCH; COGNITIVE DEFECT; COMPREHENSION; CONSENSUS; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE REGISTRY; DRUG INDUSTRY; HUMAN; HUMAN GENOME; ITALY; MYOTONIC DYSTROPHY; NEUROIMAGING; NEUROPATHOLOGY; NOMENCLATURE; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; PROTEIN DEPLETION; QUALITY OF LIFE; TREATMENT PLANNING; TREND STUDY; ANIMAL; BRAIN; CONSENSUS DEVELOPMENT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REGISTER;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MYOTONIC DYSTROPHY; QUALITY OF LIFE; REGISTRIES; TERMINOLOGY AS TOPIC;

EID: 84899105416     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.01.013     Document Type: Article

References (31)

1. Axford M.M., Pearson C.E. Illuminating CNS and cognitive issues in myotonic dystrophy: workshop report. Neuromuscul Disord 2013, 23(4):370-374.
2. Winblad S., Månsson J.E., Blennow K., Jensen C., Samuelsson L., Lindberg C. Cerebrospinal fluid tau and amyloid beta42 protein in patients with myotonic dystrophy type 1. Eur J Neurol 2008, 15(9):947-952.
3. Kroksmark A.K., Ekstrom A.B., Bjorck E., Tulinius M. Myotonic dystrophy: muscle involvement in relation to disease type and size of expanded CTG-repeat sequence. Dev Med Child Neurol 2005, 47:478-485.
4. Echenne B., Rideau A., Roubertie A., Sebire G., Rivier F., Lemieux B. Myotonic dystrophy type I in childhood long-term evolution in patients surviving the neonatal period. Eur J Paediatr Neurol 2008, 12:210-223.
5. Ekström A.B., Hakenäs-Plate L., Tulinius M., Wentz E. Cognition and adaptive skills in myotonic dystrophy type 1: a study of 55 individuals with congenital and childhood forms. Dev Med Child Neurol 2009, 51(12):982-990.
6. Koch M.C., Grimm T., Harley H.G., Harper P.S. Genetic risks for children of women with myotonic dystrophy. Am J Hum Genet 1991, 48:1084-1091.
7. Angeard N., Gargiulo M., Jacquette A., Ravanyi H., Eymard B., Hèron D. Cognitive profile in childhood myotonic dystrophy: is there a global impairment?. Neuromuscul Disord 2007, 17:451-458.
8. Heatwole C., Bode R., Johnson N., et al. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 2012, 79(4):348-357.
9. Johnson NE, Luebbe E, Eastwood E, Chin N, Moxley RT 3rd, Heatwole CR. The impact of congenital and childhood myotonic dystrophy on quality of life: a qualitative study of associated symptoms. J Child Neurol 2013. [Epub ahead of print].
10. Angeard N., Jacquette A., Gargiulo M., et al. A new window on neurocognitive dysfunction in the childhood form of myotonic dystrophy type 1 (DM1). Neuromuscul Disord 2011, 21(7):468-476.
11. Cohen D., Plaza M., Perez-Diaz F., et al. Individual cognitive training of reading disability improves word identification and sentence comprehension in adults with mild mental retardation. Res Dev Disabil 2006, 27(5):501-516.
12. Douniol M., Jacquette A., Cohen D., et al. Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1. Dev Med Child Neurol 2012, 54(10):905-911.
13. Ekström A.B., Hakenas-Plate L., Samuelsson L., et al. Autism spectrum conditions in myotonic dystrophy type 1: a study on 57 individuals with congenital and childhood forms. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:918-926.
14. Gagnon C., Meola G., Hébert L.J., Puymirat J., Laberge L., Leone M. Report of the first outcome measures in myotonic dystrophy type 1 (OMMYD-1) international workshop: Clearwater, Florida, November 30, 2011. Neuromuscul Disord 2013, 23(12):1056-1068.
15. Meola G., Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 2007, 36(3):294-306.
16. Minnerop M., Weber B., Schoene-Bake J.C., et al. The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease. Brain 2011, 134(Pt 12):3530-3546.
17. Wozniak J.R., Mueller B.A., Bell C.J., Muetzel R.L., Lim K.O., Day J.W. Diffusion tensor imaging reveals widespread white matter abnormalities in children and adolescents with myotonic dystrophy type 1. J Neurol 2013, 260:1122-1131.
18. Axer M., Grässel D., Kleiner M., et al. High-resolution fiber tract reconstruction in the human brain by means of three-dimensional polarized light imaging. Front Neuroinformatics 2011, 5:34.
19. Day J.W., Ranum L.P. RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord 2005, 15(1):5-16.
20. Charizanis K., Lee K.Y., Batra R. Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron 2012, 75(3):437-450.
21. Wang E.T., Cody N.A., Jog S., et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 2012, 150(4):710-724.
22. Zu T., Gibbens B., Doty N.S., et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci USA 2011, 108(1):260-265.
23. Hernández-Hernández O., Guiraud-Dogan C., Sicot G., et al. Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour. Brain 2013, 136(Pt 3):957-970.
24. Oyamada R., Hayashi M., Katoh Y., et al. Neurofibrillary tangles and deposition of oxidative products in the brain in cases of myotonic dystrophy. Neuropathology 2006, 26(2):107-114.
25. Machuca-Tzili L.E., Buxton S., Thorpe A., et al. Zebrafish deficient for muscleblind-like 2 exhibit features of myotonic dystrophy. Dis Model Mech 2011, 4(3):381-392.
26. Spilker K.A., Wang G.J., Tugizova M.S., Shen K. Caenorhabditis elegans muscleblind homolog mbl-1 functions in neurons to regulate synapse formation. Neural Dev 2012, 7:7.
27. Garcia-Lopez A., Monferrer L., Garcia-Alcover I., Vicente-Crespo M., Alvarez-Abril M.C., Artero R.D. Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS One 2008, 3(2):e1595.
28. Deramecourt V., Lebert F., Debachy B., et al. Prediction of pathology in primary progressive language and speech disorders. Neurology 2010, 74(1):42-49.
29. Butti C., Santos M., Uppal N., Hof P.R. Von Economo neurons: clinical and evolutionary perspectives. Cortex 2013, 49(1):312-326.
30. Thompson R., Schoser B., Monckton D.G., Blonsky K., Lochmüller H. Patient registries and trial readiness in myotonic dystrophy. TREAT-NMD/Marigold International Workshop Report. Neuromuscul Disord 2009, 19(12):860-866.
31. Wheeler T.M., Sobczak K., Lueck J.D., et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009, 325(5938):336-339.